Prosecution Insights
Last updated: November 04, 2026
Application No. 19/038,050

DEVICE FOR FACILITATING THE IMPLANTATION OF A SURGICAL MESH

Non-Final OA §102§103§112
Filed
Jan 27, 2025
Priority
Mar 24, 2021 — FR 2102931 +1 more
Examiner
OU, JING RUI
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sofradim Production
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
2y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
426 granted / 795 resolved
-16.4% vs TC avg
Strong +52% interview lift
Without
With
+51.5%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
47 currently pending
Career history
840
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
42.8%
+2.8% vs TC avg
§102
24.0%
-16.0% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 795 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to the election/restriction response filed on 07/27/2026. Claims 19-37 are pending. Claims 19 and 37 are independent. Claim 37 has been withdrawn from consideration by the applicant. Claim 28 is withdrawn by the examiner for the reason(s) stated below Election/Restrictions Applicant’s election of Group I (claims 19-36) and Species A (Figures 6-9) in the reply filed on 07/27/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim 37 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/27/2026. Applicant indicated the claims 19-36 are readable on the elected species. However, claim 28 is not readable on the elected species (Species A, Figs. 6-9) by reciting “the at least one biocompatible film is provided with a precut line, the precut line being substantially aligned on the slit.” Instead, it is directed to the non-elected species, Species B (Figure 12). Therefore claim 28 is withdrawn from consideration. Claim Objections Claim 19 is objected to because of the following informalities: Claim 19, line 7, the limitation “the implantable surgical mesh” should be amended to --the surgical mesh-- to be consistent with the other claim limitations in claim 19. Appropriate correction is required. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Currently, none of the claim limitations are interpreted under 35 U.S.C. 112(f). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 26 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 26 recites the limitation "the edge" in line 2 of the claim. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 19, 21, 23, 25-27, and 36 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Paul (US Pub. No.: 2012/0259348). Regarding claims 19, 21, 23, 25-27, and 36, Paul discloses [claim 19] a device comprising: a surgical mesh (102, Figs 2 or 5 and Fig. 3) having a barbed face (106, Fig. 3 and Para. [0041]) defining a longitudinal axis between a first end and an opposite second end (Fig. 1), the surgical mesh configured to be implanted into a patient; at least one biocompatible film (302, Fig. 3 and Para. [0044]) shaped and dimensioned to cover a majority of barbs (304, Fig. 3) on the barbed face while leaving a portion of barbs uncovered on at least one of the first end or second end of the barbed face (Fig. 3 and Para. [0044]), the at least one biocompatible film being configured to be detached from the implantable surgical mesh and removed from the patient after the surgical mesh is correctly positioned in the patient (Para. [0044]-[0046]); [claim 21] wherein the at least one biocompatible film is made from biodegradable materials only (Para. [0044]-[0046]); [claim 23] wherein the at least one biocompatible film is shaped and dimensioned to leave portions of barbs uncovered on both the first end and the second end of the barbed face (Para. [0044]-[0046], the at least one biocompatible film is shaped and dimensioned to leave portions of barbs uncovered on both the first end and the second end of the barbed face once it is dissolved); [claim 25] wherein the surgical mesh includes a slit (Paras. [0037], [0005], and [0006] and Figs. 2 or 5) for allowing the passage of the spermatic cord; [claim 26] wherein the surgical mesh further includes a flap (202, Fig. 2 or 5), extending from the edge of the slit, the flap being intended to close the surgical mesh around the spermatic cord once the surgical mesh is implanted; [claim 27] wherein the at least one biocompatible film shows a flexibility allowing it to be folded to pass through the slit once the at least one biocompatible film is detached from the surgical mesh (Para. [0047], the at least one biocompatible film shows a flexibility which is fully capable to allow it to be folded to pass through the slit once the at least one biocompatible film is detached from the surgical mesh since as by physically cutting a portion of the film or mesh with film to fold it to pass through the slit); [claim 36] wherein the mesh has a globally oval shape (Fig. 2 or 5) Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Paul (US Pub. No.: 2012/0259348) as applied to claim 19 above, and further in view of Lecuivre et al. (US Pub. No.: 2014/0330295). Regarding claim 20, Paul discloses all the limitations of claim 19 as taught above but fails to disclose that the at least one biocompatible film is non-porous. Lecuivre teaches, in the same field of endeavor (surgical device with a coating), at least one biocompatible film (7, Fig. 9C) for covering barbs is non-porous (Paras. [0120] and [0121]). Before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to modify the at least one biocompatible film of Paul to be non-porous as taught by Lecuivre in order to maintain its integrity before its introducing into the delivery device (Lecuivre, Para. [0065]). Claim(s) 22 is/are rejected under 35 U.S.C. 103 as being unpatentable over Paul (US Pub. No.: 2012/0259348) as applied to claim 19 above, and further in view of Roby et al. (US Pat. No.: 6,235,869). Regarding claim 22, Paul discloses all the limitations of claim 19 and further discloses that the film is obtained via lamination (Para. [0046] and Fig. 3). However, Paul does not disclose that the material for forming the film is poly(glycolide-caprolactone-lactide-trimethylene carbonate). Roby teaches, in the same field of endeavor (coating film for surgical articles), a coating film for a surgical article is formed of poly(glycolide-caprolactone-lactide-trimethylene carbonate) (see Abstract and Col. 2, line 58 – Col. 3, line 42). Before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to modify the at least one biocompatible film of Paul to be formed of poly(glycolide-caprolactone-lactide-trimethylene carbonate) as taught by Roby, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use. See MPEP 2144.07 Claim(s) 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Paul (US Pub. No.: 2012/0259348). Regarding claim 24, Paul discloses all the limitations of claim 19 as taught above but fails to disclose that the film has a thickness ranging from about 15 microns to about 25 microns. However, Paul discloses that the thickness can be 1.5 to 1.2 mm and other thickness can be used. Before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to modify the thickness of the film to be ranging from about 15 microns to about 25 microns in order to accommodate different size of the barbs or naps, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. See MPEP 2144.05 Allowable Subject Matter Claims 29-35 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US 20140257517 A1 Deichmann; Thorsten et al. discloses a surgical implant having a mesh and barbed face. US 20210085442 A1 Felder; John discloses a surgical implant having a mesh and barbed face. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JING RUI OU whose telephone number is (571)270-5036. The examiner can normally be reached M-F 9:00am -5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jackie Ho can be reached at (571) 272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JING RUI OU/ Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jan 27, 2025
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779182
Balloon Stent
6y 10m to grant Granted Nov 03, 2026
Patent 12778584
VASCULAR ANASTOMOSIS DEVICE
3y 10m to grant Granted Nov 03, 2026
Patent 12778595
HEMOSTATIC DEVICE
3y 1m to grant Granted Nov 03, 2026
Patent 12758228
IMPLANTABLE EMBOLIZATION DEVICE
4y 3m to grant Granted Oct 13, 2026
Patent 12740879
MODULAR HANDLE COMPRISING A TRIGGER WIRE ACTUATION MECHANISM FOR A PROSTHESIS DELIVERY DEVICE
2y 3m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+51.5%)
4y 3m (~2y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month